Immunomodulatory ADCs: A New Weapon Against Autoimmune Diseases
▎This article is contributed by Ying’en Biotech (slightly edited) Since the first antibody-drug conjugate (ADC) was approved for the treatment of acute myeloid leukemia in 2000, after more than twenty years of exploration and development, 14 ADC drugs have been successfully approved for clinical treatment of tumors. In August 2022, the FDA announced the accelerated … Read more